{"gao_id": "GAO-18-556T", "published": "2018-05-15T12:00:00Z", "released": "2018-05-15T08:00:00Z", "summary": "The \"340B\" program requires drug manufacturers to sell outpatient drugs to covered entities\u2014certain hospitals and federal grantees (like health centers and clinics)\u2014at a discount to have their drugs covered under Medicaid. This testimony describes the Health Resources & Services Administration's oversight of the 340B Program. In 2011 we made recommendations to HRSA to address weaknesses we identified in its oversight of the program. HRSA has...", "title": "Drug Discount Program: Status of Agency Efforts to Improve 340B Program Oversight", "topics": ["Drug prices", "Medicaid", "Patient care", "Health Care", "Health care centers", "Hospitals", "Drugs", "Pharmacy", "Program management", "Health care", "Compliance oversight"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-18-556t", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-18-556t-highlights.pdf"}, {"title": "Full Report (18 pages)", "url": "https://www.gao.gov/assets/gao-18-556t.pdf"}, {"title": "Accessible PDF (19 pages)", "url": "https://www.gao.gov/assets/700/692038.pdf"}]}